HOPE Therapeutics™, Inc., (“HOPE”), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (“NRx”, and collectively with HOPE, the “Company”) (Nasdaq:NRXP), today announced it conducted an investor workshop to support planned expansion of HOPE’s network of interventional psychiatry practices focused on the treatment of suicidal depression and PTSD, at the Mar-A-Lago Club in Palm Beach, FL.
The event was attended by Qualified Institutional Buyers as defined by the Securities and Exchange Commission and included Jonathan Javitt, MD, MPH, Chairman and CEO of NRx together with Dallas Sauer, Founder of Smith and Sauer, the private investment firm that recently committed to invest in both NRx and HOPE. No formal meetings were conducted with members of the incoming administration.
Key areas of investor discussions included:
- HOPE’s mission to build an international network of best-in class, EBITDA positive, interventional psychiatry clinics
- $25 million financing committed by Smith and Sauer (JGS Holdings LLC) to leverage anticipated bank financing projected to secure $100 million in HOPE clinic revenue stream on a pro-forma basis
- Recently announced progress for HOPE’s initial clinic acquisitions
- Potential mechanisms for follow-on non-dilutive financing to expand HOPE’s network by an additional 50 clinics in 2026 and 100 clinics in 2027
- Plans for integration of new technologies and a CRM-based information technology and telepsychiatry umbrella to span the HOPE network
Based on the results of today’s meeting, NRx has been invited to return to Mar-A-Lago for an expanded meeting during the last week of January 2025 that will include both Qualified Institutional Buyers and Accredited Investors. Individuals interested in attending are invited to contact Matthew Duffy, Co-CEO of HOPE Therapeutics.
“We were gratified by the enthusiastic response and inciteful questions we received from this group of sophisticated attendees and look forward to future discussions,” said Jonathan Javitt, MD MPH, Founder, Chairman & CEO of NRx, and Co-CEO HOPE Therapeutics. “Our mission to treat and prevent suicidality in our society in general, and our military/veteran communities in particular, clearly resonated with those who joined us this evening.”
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.